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The majority of lung cancer is caused by tobacco smoking, and lung cancer-relevant epigenetic markers 
have been identified in relation to smoking exposure. Still, smoking-related markers appear to mediate 
little of the effect of smoking on lung cancer. Thus in order to identify disease-relevant markers and 
enhance our understanding of pathways, a wide search is warranted. Through an epigenome-wide 
search within a case-control study (131 cases, 129 controls) nested in a Norwegian prospective cohort of 
women, we found 25 CpG sites associated with lung cancer. Twenty-three were classified as associated 
with smoking (LC-AwS), and two were classified as unassociated with smoking (LC-non-AwS), as they 
remained associated with lung cancer after stringent adjustment for smoking exposure using the 
comprehensive smoking index (CSI): cg10151248 (PC, CSI-adjusted odds ratio (OR) = 0.34 [0.23–0.52] 
per standard deviation change in methylation) and cg13482620 (B3GNTL1, CSI-adjusted OR = 0.33 
[0.22–0.50]). Analysis among never smokers and a cohort of smoking-discordant twins confirmed the 
classification of the two LC-non-AwS CpG sites. Gene expression profiles demonstrated that the LC-AwS 
CpG sites had different enriched pathways than LC-non-AwS sites. In conclusion, using blood-derived 
DNA methylation and gene expression profiles from a prospective lung cancer case-control study in 
women, we identified 25 CpG lung cancer markers prior to diagnosis, two of which were LC-non-AwS 
markers and related to distinct pathways.
Lung cancer is the leading cause of cancer death worldwide, causing as many deaths as the next four most deadly 
cancers combined (breast, prostate, colon, and pancreas), and the incidence of lung cancer is projected to double 
by 20501.
Recent advances in molecular biology, and the emergence of cost efficient OMICs data has contributed new 
insight into mechanisms involved in lung carcinogenesis. For instance, several epigenome-wide association stud-
ies have identified methylation changes that are associated with lung cancer risk2–8, using mainly tumor tissue 
collected at the time of diagnosis, but also blood in prevalent cases9. Other studies focusing on established lung 
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carcinogens such as smoking used peripheral blood and identified several differentially methylated CpG sites10–13. 
Of these, a recent meta-analysis including 15,907 participants identified 2,623 differentially methylated CpG sites 
in relation to smoking status14.
Although smoking is an established causal risk factor responsible for a vast proportion of lung cancer inci-
dence, identified smoking-related CpG sites have been shown to mediate some or little of the effects of smoking 
on lung cancer6,15. Further, the most common histological subtype of lung cancer in never smokers is adenocar-
cinoma16, which might originate from specific, and as yet unknown, molecular mechanisms different from those 
involved in smoking-induced lung cancer17. It is therefore of interest to identify lung cancer biomarkers that are 
unrelated to smoking exposure to (i) gain better understanding of the etiology of lung cancer and (ii) to investi-
gate whether biological pathways affected by smoking-induced changes in DNA-methylation are similar to those 
affected by differential methylation at CpG sites that are not associated with smoking exposure. To-date, very few 
studies have investigated methylation markers of lung cancer risk that are not associated with such exposure8,18.
In the current study, we used full-resolution DNA methylation profiles from prospectively collected blood 
samples to identify methylation alterations in relation to future lung cancer diagnosis and assess the relation-
ship between these markers and smoking exposure. Specifically, we adopted a stringent adjustment strategy to 
identify disease-related methylation changes at CpG sites that are not associated with smoking exposure and 
compare them to changes in methylation level at disease-related CpG sites that are also associated with smoking 
exposure. Finally, we exploited gene expression data measured in the same individuals to aid functional inter-
pretation by exploring biological pathways of gene expression profiles affected by methylation changes at all lung 
cancer-related CpG sites.
Materials and Methods
Participants. Our study population included women from a lung cancer case–control study nested in the 
post genome cohort (N ~ 50 000) within the Norwegian Women and Cancer Study (NOWAC)19–21. All partici-
pating women were cancer-free at recruitment (1991–2006) and at time of blood sampling (2003–2006). Linkage 
to the national cancer registry identified 134 incident lung cancer cases. Cases were diagnosed between 2004 and 
2011, and for each case, one control was matched on time since blood sampling and birth year. All participants 
gave written informed consent and the study was approved by the Regional Committee for Medical and Health 
Research Ethics and the Norwegian Data Inspectorate. We confirm that all methods employed in the study were 
performed in accordance with the relevant guidelines and regulations.
We used methylation data from the Netherlands Twin Register (NTR) for replication. Subjects in the NTR 
biobank study were recruited between 2004 and 201122,23. The study included 769 monozygotic (MZ) and 424 
dizygotic (DZ) twin pairs. A blood sample was collected at inclusion and we included in the present study 125 MZ 
and 146 DZ adult twin pairs who were discordant with respect to their smoking status at time of blood sampling. 
We included pairs in which one twin never smoked and the other twin was a current smoker (N = 53 MZ, and 77 
DZ), and pairs including one never smoker and one former smoker (N = 72 MZ, and 69 DZ).
DNA methylation and gene expression microarray data. Genome-wide DNA methylation profiles 
from bisulphite-converted, hybridized genomic DNA from buffy coat samples were generated using Illumina 
Infinium HumanMethylation450 Bead-Chips following a protocol described previously for both NOWAC24 and 
NTR22,25 samples. DNA methylation levels at each locus were expressed as the ratio of intensities arising from 
methylated cytosines over total intensities. For NOWAC, sample preparation and data pre-processing were per-
formed as described elsewhere24. In brief, probes (i) on sex chromosomes, (ii) reported to be cross-reactive26 and 
(iii) for which methylation levels were measured in <20% of the samples were excluded. Five samples did not pass 
quality controls and three subjects were excluded due to >95% missing in DNA methylation results. The final 
analysis included 428,629 probes targeting autosomal CpG loci in 260 women (131 cases and 129 controls). In 
NTR data, sample- and probe-level quality checks and data pre-processing were performed as described in detail 
previously25 and only CpG sites identified in the NOWAC discovery data were interrogated.
For 248 of the 260 women from the NOWAC study with DNA methylation data, gene expression profiles were 
also available and were generated at the Norwegian University of Science and Technology. Total RNA was isolated 
using established protocols27 and microarray analyses were performed using the IlluminaHuman HT-12 expres-
sion Bead-Chips. Microarray data were quality-checked and pre-processed as previously described28. Original 
probe values were background-corrected and probes reported to have poor quality from Illumina or detected in 
<95% of samples were filtered out. Only transcripts on autosomal chromosomes were included in the analysis. 
The final gene expression data set included 18,955 transcripts assayed in 248 individuals.
Statistical models. We investigated the relationship between future lung cancer status and methylation lev-
els using unconditional logistic regression models. As already described29, we corrected for technically-induced 
variation in methylation and gene expression data by fitting a preliminary linear mixed model including technical 
covariates (chip ID and position on the chip for methylation data and date of mRNA isolation and date of com-
plementary RNA generation for gene expression data) as random intercepts, and, to account for the case control 
matching we adjusted (fixed effects) our models for the two matching criteria: age at blood collection and sample 
storage time.
Methylation and gene expression levels used in the downstream analyses were represented by the residu-
als from these mixed models. Multiple testing was accounted for by using a Bonferroni correction ensuring a 
family-wise error rate below 5% (corresponding per test significance level was set to 1.16e-07). We report as effect 
size estimates the odds ratios (OR) for one standard deviation change in the methylation levels.
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We further adjusted the logistic regression models for blood cell composition, estimated according to the 
methods proposed by Houseman30,31. We specifically adjusted for estimated proportions of leukocytes (excluding 
natural killer cells and eosinophil granulocytes).
Lung cancer-related CpG sites that are not associated with smoking exposure (LC-non-AwS) were defined as 
those (i) found significantly associated to lung cancer in the main logistic model, and (ii) remaining associated 
to lung cancer upon adjustment for smoking. Conversely, lung cancer-related CpG sites that are associated with 
smoking exposure (LC-AwS) are defined as those losing statistical significance upon adjustment for smoking 
exposure. Confirmation of their lack of association to smoking exposure was sought in never smokers and an 
independent study including smoking-discordant twins. We investigated three measures of smoking exposure: 
smoking status, pack-years, and the comprehensive smoking index (CSI)32. CSI scores (Table S1) were obtained 
using duration of smoking (dur; years), intensity (int; average number of cigarettes per day during years of smok-
ing), and time since smoking cessation (tsc; years) and fitting the following model to our data:
X2 = (1 − 0.5dur∗/τ)(0.5tsc∗/τ) ln(int + 1), where τ is the estimated half-life parameter, and δ is an esti-
mated lag time parameter describing tsc and total duration as follows: tsc∗ = max(tsc − δ, 0) and 
dur∗ = max(dur + tsc − δ) − tsc∗.
To further assess possible relations between methylation levels at disease-related sites and smoking exposure, 
we used the methylation data of the NTR study and ran paired Student’s T-test analyses comparing the mean 
methylation differences within pairs of MZ and DZ smoking discordant twins. Paired T-tests were performed 
on residual methylation levels, which were obtained by adjusting the methylation levels (beta-values) for sex, age 
at blood sampling, measured cell counts (percentage of monocytes, eosinophils, and neutrophils), and technical 
covariates: array row and sample plate.
We ran a series of sensitivity analyses that included conditional logistic regressions for the (N = 128) case-control 
complete pairs. Further sensitivity analyses were restricted to (i) cases from each of the main histological subtypes sep-
arately (adenocarcinomas (N = 64), small cell and squamous (N = 43), others (N = 24))33, (ii) cases diagnosed before 
or after the median time elapsed from blood collection to diagnosis (4.2 years), (iii) cases that were current (N = 81), 
former (N = 36), or never (N = 14) smokers, separately. In these stratified analyses subsets of cases were compared 
to all healthy controls (N = 37, 35, 57 in current, former and never smokers) included in the study and, because 
case-control pairs were broken, we used unconditional logistic regression models as defined for the main analysis.
In order to ensure a wide explorative search of (N = n1) LC-non-AwS markers, which are likely weaker and less 
numerous than the (N = n2) LC-AwS markers, we complemented our list of n1 LC-non-AwS markers by defining 
a ‘second order’ set of (N = n1′) LC-non-AwS CpG sites as defined by those associated to a least one of the n1 
LC-non-AwS markers, but not directly to disease status. These were identified by regressing the methylation levels 
of the n1 LC-non-AwS CpG sites against the (428,629 − n1) remaining CpG sites. As before, we used Bonferroni 
corrected per-test significance level here defined as 0.05/(n1x(428,629 − n1)).
In order to help functional interpretation of the resulting epigenetic alterations, gene expression data meas-
ured in the same individuals were linked to the DNA methylation levels of the identified markers. Specifically, 
we ran linear regression models assessing the association between the 18,955 assayed transcripts and (i) each of 
the first and second order (n1 + n1′) LC-non-AwS CpG sites and (ii) each of the n2 LC-AwS CpG sites. Statistical 
significance of each CpG-transcript pair was evaluated adopting a Bonferroni corrected per-test significance 
level (0.05/((n1 + n1′) × 18,955), and 0.05/(n2 × 18,955), respectively). The transcripts involved in any significant 
CpG-transcript pair were subsequently included in overrepresentation analyses based on hypergeometric tests 
setting a nominal p-value of 0.05 using the ‘enrichGO’ function of the Bioconductor ‘clusterProfiler‘ package34. 
All statistical analyses were performed using R (ver. 3.1.2, Foundation for Statistical Computing, Vienna, Austria).
Variable
NOWAC study NTR study
Cases N = 131 Controls N = 129
Monozygotic N = 250 
(125 pairs)
Dizygotic N = 292 
(146 pairs)
Mean SD Mean SD Mean SD Mean SD
Age at sample 56.55 4.01 56.57 3.98 37.77 11.91 33.24 8.18
Age at diagnosis 60.5 4.12
Time to diagnosis 3.88 1.99
Pack-years 20.46 13.3 8.62 11.18
CSI 1.3 0.65 0.63 0.71
N % N % N % N %
Histological subtypes
Adenocarcinomas 64 48.9
Small cell carcinomas 25 19.1
Squamous cell carcinomas 18 13.7
Others 24 18.3
Smoking status
Current 81 61.8 37 28.68 53 21.2 77 26.4
Former 36 27.5 35 27.13 72 28.8 69 23.6
Never 14 10.7 57 44.19 125 50 146 50
Table 1. Characteristics of the NOWAC (women only) and the NTR populations.
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Results
Sample description and overall lung cancer risk. Baseline characteristics of the NOWAC women and 
NTR study populations are summarized in Table 1. As expected, NOWAC cases were more commonly current 
smokers at blood sampling (62%) than controls (29%) (Table S1). Logistic regression models demonstrated ele-
vated lung cancer risk in former smokers (OR = 4.07 (95% CI: 1.97–8.79), and in current smokers (OR = 8.46 
(95% CI: 4.31–17.53)) as compared to never smokers. The model including CSI score alone indicated an OR of 
3.66 (95% CI: 2.53–5.42) for one unit increase in CSI values and the model provided the better fit compared to 
other smoking metrics (including smoking status and pack years, AIC results not shown). Estimated cell type 
proportions were similar in cases and controls, except for the natural killer cells, which were underrepresented in 
cases and among current smokers (Table S2).
Differentially methylated CpG sites associated to lung cancer risk. We identified 25 CpG sites at 
which lower methylation levels were associated to higher lung cancer risk (Tables 2 and S3; boxplots of the meth-
ylation according to case/control status in Figure S1 and volcano plot in Figure S2). After adjustment for smoking, 
n2 = 23 of these sites were classified as LC-AwS markers, as their associations lost statistical significance (Table 2). 
Among the different smoking metrics considered, CSI appeared to provide the most stringent adjustment as 
depicted by flattened p-value distribution (Figure S3, estimates for the covariates adjusted for are presented in 
Table S4). Only n1 = 2 CpGs remained associated with lung cancer risk after controlling for CSI and were clas-
sified as LC-non-AwS markers (Table 2): cg10151248; PC (OR = 0.34) and cg13482620; B3GNTL1 (OR = 0.33). 
These two LC-non-AwS CpGs were also significantly associated with lung cancer after further adjustment for 
blood cell composition (Table S5). The correlations between the n1 = 2 LC-non-AwS CpG sites and the n2 = 23 
Probe ID Gene name Chromosome
Unadjusted model Adjusted model - smoking status Adjusted model - pack-years Adjusted model - CSI
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
LC-Non-AwS CpG sites
cg10151248 PC 11 0.36 0.25–0.51 1.2E-08 0.36 0.25–0.52 7.2E-08 0.35 0.24–0.51 5.0E-08 0.34 0.23–0.5 7.1E-08
cg13482620 B3GNTL1 17 0.41 0.3–0.57 8.5E-08 0.39 0.27–0.55 2.1E-07 0.33 0.22–0.5 6.7E-08 0.33 0.22–0.5 8.4E-08
LC-AwS CpG sites
cg05575921 AHRR 5 0.37 0.27–0.49 2.9E-11 0.38 0.23–0.64 2.5E-04 0.55 0.37–0.81 2.2E-03 0.56 0.35–0.9 1.6E-02
cg03636183 F2RL3 19 0.38 0.28–0.52 2.5E-10 0.49 0.32–0.75 8.5E-04 0.58 0.4–0.83 3.2E-03 0.58 0.38–0.89 1.2E-02
cg06126421 NA 6 0.38 0.28–0.52 8.6E-10 0.54 0.36–0.8 2.1E-03 0.59 0.41–0.85 4.7E-03 0.63 0.42–0.94 2.5E-02
cg21566642 NA 2 0.42 0.31–0.56 2.5E-09 0.60 0.38–0.94 2.7E-02 0.67 0.46–0.98 3.7E-02 0.69 0.43–1.11 1.3E-01
cg02152091 NA 8 0.39 0.29–0.53 3.7E-09 0.39 0.28–0.55 2.8E-08 0.40 0.28–0.55 6.5E-08 0.43 0.31–0.6 5.3E-07
cg03898802 DOPEY2 21 0.39 0.28–0.53 6.8E-09 0.41 0.29–0.58 2.6E-07 0.41 0.29–0.58 4.4E-07 0.42 0.29–0.59 8.7E-07
cg06500852 NA 2 0.40 0.29–0.55 7.8E-09 0.43 0.31–0.6 5.7E-07 0.45 0.33–0.63 2.5E-06 0.46 0.33–0.64 4.9E-06
cg20024310 NA 7 0.37 0.26–0.52 1.7E-08 0.35 0.24–0.52 9.2E-08 0.36 0.24–0.53 2.7E-07 0.36 0.24–0.54 6.0E-07
cg06368429 KPNA7 7 0.39 0.28–0.54 1.9E-08 0.44 0.31–0.61 2.0E-06 0.41 0.28–0.58 5.6E-07 0.43 0.3–0.62 4.1E-06
cg02451831 KIAA0087 7 0.41 0.3–0.56 1.9E-08 0.50 0.35–0.7 8.4E-05 0.53 0.38–0.74 1.9E-04 0.54 0.39–0.76 4.0E-04
cg13936208 NA 12 0.38 0.27–0.53 2.1E-08 0.38 0.26–0.55 3.7E-07 0.42 0.29–0.6 2.1E-06 0.41 0.29–0.6 2.8E-06
cg13525026 MYO15A 17 0.43 0.32–0.58 2.3E-08 0.48 0.35–0.66 5.0E-06 0.48 0.35–0.66 7.8E-06 0.48 0.34–0.66 9.6E-06
cg08928494 CA5A 16 0.39 0.28–0.55 2.7E-08 0.41 0.29–0.58 5.8E-07 0.39 0.27–0.57 4.7E-07 0.40 0.28–0.58 8.6E-07
cg25305703 NA 8 0.43 0.32–0.58 3.2E-08 0.56 0.4–0.78 6.0E-04 0.57 0.41–0.79 6.4E-04 0.61 0.44–0.85 3.3E-03
cg00395990 PDZD3 11 0.42 0.31–0.57 3.7E-08 0.46 0.34–0.64 3.3E-06 0.48 0.34–0.66 1.2E-05 0.50 0.36–0.69 3.8E-05
cg25324976 CSHL1 17 0.43 0.31–0.58 6.0E-08 0.45 0.32–0.63 2.7E-06 0.45 0.32–0.63 5.6E-06 0.48 0.34–0.67 2.1E-05
cg01940273 NA 2 0.46 0.35–0.61 6.1E-08 0.67 0.44–1 5.1E-02 0.73 0.51–1.03 7.1E-02 0.79 0.53–1.17 2.4E-01
cg11635401 MYO9B 19 0.43 0.31–0.58 9.1E-08 0.40 0.28–0.57 3.0E-07 0.40 0.28–0.57 2.5E-07 0.41 0.29–0.58 5.7E-07
cg22475974 NA 4 0.44 0.33–0.6 9.2E-08 0.47 0.34–0.64 2.2E-06 0.48 0.35–0.65 3.6E-06 0.50 0.37–0.69 2.1E-05
cg21838013 CRTAM 11 0.41 0.3–0.57 1.0E-07 0.44 0.31–0.62 2.1E-06 0.42 0.3–0.6 1.3E-06 0.45 0.32–0.64 6.3E-06
cg23069177 OCA2 15 0.43 0.31–0.58 1.0E-07 0.43 0.3–0.6 1.7E-06 0.43 0.31–0.61 2.3E-06 0.41 0.29–0.59 1.4E-06
cg21161138 AHRR 5 0.45 0.34–0.61 1.0E-07 0.66 0.45–0.95 2.7E-02 0.70 0.5–0.97 3.3E-02 0.77 0.54–1.11 1.6E-01
cg16976547 FES 15 0.42 0.31–0.58 1.1E-07 0.44 0.31–0.62 3.2E-06 0.45 0.32–0.64 6.4E-06 0.46 0.33–0.66 1.6E-05
Table 2. 25 Bonferroni significant CpG sites differentially methylated in cases as compared to controls 
(N = 131 cases, 129 controls) that were un-associated with smoking (LC-non-AwS), or associated with smoking 
(LC-AwS). OR, odds ratio; CI, confidence interval. Regression models include residual DNA methylation 
levels (DNA methylation adjusted for technical covariates and matching variables; see Method section) as 
an independent variable. Results are presented for the unadjusted unconditional logistic regression and the 
same model adjusted for three selected smoking metrics (smoking status as categories never/former/current, 
pack-years, and comprehensive smoking index (CSI)). Model results for unconditional logistic regressions 
adjusted for WBCs and CSI + WBCs are presented in Table S4. Bolded p-values are significant according to the 
Bonferroni threshold.
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LC-AwS sites were moderate (Fig. 1). Conversely, we observed stronger block correlations within the LC-AwS 
sites, and in particular a subset of eight CpG sites (Figure S4). Results in figures and tables are presented separately 
for LC-AwS and LC-non-AwS sites.
The two LC-non-AwS CpG sites were also associated with lung cancer risk in never smokers (OR = 0.36 (95% 
CI: 0.17–0.77) and OR = 0.31 (95% CI: 0.14–0.67) for cg10151248-PC and cg13482620-B3GNTL1, respectively). 
Estimates were consistent in current smokers for cg10151248-PC and cg13482620-B3GNTL1 (OR = 0.32 (95% CI: 
0.19–0.57) and OR = 0.33 (95% CI: 0.18–0.61)), respectively) but slightly weaker in former smokers (OR = 0.43 
(95% CI: 0.23–0.82) and 0.50 (95% CI: 0.30–0.85)). The stratified analysis showed that 10 CpG sites among the 23 
LC-AwS CpG sites were significantly associated to lung cancer status in never smokers (Table S6). The methyla-
tion levels of the two most strongly associated LC-AwS CpG sites: cg05575921-AHRR and cg03636183-F2RL3, 
were not associated with lung cancer risk in never smokers (OR = 0.27 (95% CI: 0.03–2.14) and 1.22 (95% CI: 
0.32–4.68), respectively.
Additional stratification on histological subtypes provided consistent OR estimates for cg10151248-PC 
across histological subtypes (Table S7; range: 0.36–0.39), and stronger effects of methylation levels were esti-
mated in cases with shorter time to diagnosis (0.33 vs 0.41 for short and long time to diagnosis, respectively). For 
cg13482620-B3GNTL1, effect size estimates were consistent in both time to diagnosis classes, but the OR was 
lower in adenocarcinoma cases (OR = 0.35) than in ‘all other subtypes’ and ‘squamous and small cell’ cases (OR 
>0.49). Corresponding stratified analyses for LC-AwS CpGs are also presented in Table S7.
Using conditional logistic regressions unadjusted for smoking exposure, as a sensitivity analysis, only two of 
the n1 + n2 = 25 candidate CpG sites reached Bonferroni significance level (cg05575921 and cg06126421, p-values 
3.99e−08 and 6.68e−08, respectively).
When comparing mean methylation levels for the 25 candidate CpG sites within pairs of smoking-discordant 
twins (MZ or all), we found no differences between never smokers and ever/current smokers for the two 
LC-non-AwS markers (Table 3). Comparison of the mean methylation levels at the LC-AwS CpG sites, showed 
significant differences at eight CpG sites while comparing smokers (current or ever) to never smokers. When 
restricting these comparisons to MZ twin pairs, six and eight CpG sites were significantly different in never to 
current and never to ever comparisons, respectively (Table 3).
Functional investigation of the 25 candidate CpG sites. No significant association was found linking 
DNA methylation levels at either LC-non-AwS sites (cg10151248-PC and cg13482620-B3GNTL1) and the gene 
expression levels at the 18,955 transcripts assayed (containing one transcript each for PC and B3GNTL1 genes). 
We identified a total of n1’ = 1987 ‘second order’ LC-non-AwS CpG sites whose methylation levels were associ-
ated to that of at least one of the n1 = 2 LC-non-AwS CpG sites, and not directly with disease risk. Of these, 160 
and 1,876 were associated with methylation levels of cg10151248-PC and cg13482620-B3GNTL1, respectively 
and their pairwise correlation is presented in Figure S5A. When regressing the n1’ ‘second order’ set of CpG 
sites against the gene expression levels we identified (i) 19 significant CpG-transcript pairs for cg10151248-PC 































Figure 1. Heatmap of the correlation between the two CpGs un-associated with smoking (LC-non-AwS) and 
the 23 CpGs associated with smoking (LC-AwS). Figure note: The correlation strength is represented by color as 
indicated in the bar to the right.
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pairs for cg13482620-B3GNTL1 (Table S9), including 127 unique transcripts and nine CpG sites (Table 4). The 
correlations between transcripts associated to the methylation levels of at least one ‘second order’ CpG site are 
presented in Figure S5B. Overrepresentation analyses of transcripts involved in these significant LC-non-AsW 
CpG-transcript pairs demonstrated distinct enriched ontology categories relating to immune response, and 
involving beta cells (Fig. 2, Tables S10 and S11, respectively).
For the n2 = 23 LC-AwS CpG sites we identified 168 significant CpG-transcript pairs (Tables 4 and S12), corre-
sponding to 100 unique transcripts and eight unique CpG sites. Overrepresentation analyses identified ontology 
categories distinctly different from those identified above and mostly related to responses to external stressors 
(Fig. 2 and Table S13).
Discussion
We combined genome-wide methylation and gene expression profiles from prospective blood samples in the 
NOWAC study to identify markers of lung cancer risk in Norwegian women and investigated to what extent these 
associations were driven by exposure to smoking. We identified 25 CpG sites associated with lung cancer risk, 
of which 23 were classified as LC-AwS, as they lost statistical significance after stringent adjustment for smoking 
exposure metrics. The two remaining CpG sites (cg10151248-PC and cg13482620- B3GNTL1) were classified as 
LC-non-AwS CpG sites, as they remained statistically significant after adjustment for CSI and demonstrated low 
correlation to the other 23 CpGs. For the majority of markers the case control difference was larger with shorter 
time to diagnosis.
Of the 23 LC-AwS CpG sites, eight have been acknowledged as epigenetic signatures of cigarette smoking in 
a recent large meta-analysis of DNA methylation and smoking14. Pairwise correlations among the same eight 
LC-AwS CpG sites were also markedly higher than correlations with the other 15 LC-AwS CpG sites, supporting 
the evidence of these being linked to smoking. Furthermore, the same eight LC-AwS CpG sites were differentially 
methylated in smoking discordant twins. For the majority of the 23 LC-AwS markers, the association with risk 
was also stronger in the smoking related histological subtypes as compared to adenocarcinoma. The evidence to 
classify the 23 CpG sites as LC-AwS was not equally strong, but was considered sufficient for them to be treated 
separately as LC-AwS markers in the downstream analyses.
CpG site
All twins Monozygotic twins
Never vs. Current Never vs. Ever Never vs. Current Never vs. Ever
Mean diff. 95% CI p-value Mean diff. 95% CI p-value Mean diff. 95% CI p-value Mean diff. 95% CI p-value
LC-Non-AwS CpG sites
cg10151248 −0.001 −0.003–0.001 2.7E-01 0.000 −0.002–0.001 5.1E-01 −0.002 −0.005–0 8.3E-02 0.000 −0.002–0.001 6.4E-01
cg13482620 −0.002 −0.005–0.002 3.7E-01 −0.002 −0.004–0.001 1.7E-01 −0.002 −0.008–0.004 5.6E-01 −0.002 −0.005–0.002 3.1E-01
LC-AwS CpG sites
cg05575921 0.139 0.118–0.159 7.8E-26 0.086 0.073–0.099 4.5E-31 0.132 0.1–0.164 3.0E-11 0.073 0.055–0.09 2.8E-13
cg03636183 0.065 0.053–0.077 1.4E-20 0.045 0.037–0.052 6.2E-27 0.062 0.045–0.08 2.9E-09 0.039 0.029–0.049 4.7E-13
cg06126421 0.056 0.044–0.067 1.6E-16 0.042 0.035–0.049 9.4E-27 0.050 0.033–0.067 2.9E-07 0.034 0.025–0.042 1.3E-11
cg21566642 0.092 0.077–0.107 7.5E-23 0.067 0.058–0.077 7.6E-34 0.092 0.069–0.115 1.2E-10 0.059 0.047–0.072 1.8E-15
cg02152091 −0.003 −0.007–0.002 2.0E-01 −0.003 −0.006–0 4.8E-02 0.000 −0.007–0.007 9.9E-01 −0.003 −0.007–0.001 1.6E-01
cg03898802 −0.002 −0.005–0.001 1.5E-01 −0.001 −0.003–0 1.6E-01 −0.002 −0.006–0.003 4.4E-01 0.000 −0.002–0.003 8.5E-01
cg06500852 −0.002 −0.004–0.001 1.5E-01 −0.001 −0.002–0.001 5.3E-01 −0.004 −0.008–0.001 2.6E-02 −0.002 −0.004–0.001 1.8E-01
cg20024310 −0.006 −0.011–0 6.5E-02 −0.003 −0.007–0.001 1.7E-01 −0.004 −0.012–0.005 4.1E-01 0.003 −0.003–0.009 2.7E-01
cg06368429 −0.006 −0.013–0.001 9.5E-02 −0.003 −0.007–0.001 1.6E-01 −0.008 −0.019–0.003 1.5E-01 −0.002 −0.008–0.004 5.1E-01
cg02451831 0.014 0.009–0.02 3.0E-06 0.010 0.006–0.013 1.8E-07 0.013 0.005–0.021 2.9E-03 0.008 0.003–0.013 1.2E-03
cg13936208 −0.004 −0.008–0 4.5E-02 −0.003 −0.006–0 2.2E-02 −0.003 −0.008–0.003 2.8E-01 −0.001 −0.005–0.002 4.8E-01
cg13525026 −0.003 −0.006–0.001 1.2E-01 −0.001 −0.003–0.001 2.9E-01 −0.007 −0.012–0.002 6.0E-03 −0.003 −0.007–0 5.0E-02
cg25305703 0.021 0.012–0.03 8.9E-06 0.015 0.01–0.021 3.1E-07 0.020 0.006–0.034 5.3E-03 0.013 0.005–0.021 1.2E-03
cg00395990 −0.002 −0.006–0.002 3.1E-01 −0.001 −0.003–0.001 3.2E-01 −0.002 −0.007–0.004 5.2E-01 0.000 −0.003–0.003 8.5E-01
cg01940273 0.059 0.049–0.07 2.3E-20 0.042 0.036–0.049 5.9E-29 0.058 0.042–0.074 1.7E-09 0.037 0.028–0.046 2.1E-13
cg11635401 −0.002 −0.007–0.003 4.5E-01 −0.001 −0.004–0.002 5.5E-01 −0.006 −0.014–0.002 1.5E-01 −0.003 −0.008–0.002 1.9E-01
cg22475974 0.000 −0.002–0.001 6.1E-01 0.000 −0.002–0.001 4.3E-01 −0.002 −0.004–0.001 3.0E-01 0.000 −0.002–0.001 6.5E-01
cg21838013 −0.003 −0.008–0.002 2.1E-01 −0.001 −0.005–0.003 6.0E-01 −0.001 −0.009–0.007 8.5E-01 0.002 −0.003–0.008 4.0E-01
cg23069177 −0.001 −0.005–0.003 6.2E-01 −0.001 −0.003–0.002 5.6E-01 0.000 −0.006–0.006 9.4E-01 −0.001 −0.005–0.003 6.0E-01
cg21161138 0.044 0.036–0.052 1.1E-20 0.026 0.021–0.031 4.3E-20 0.044 0.031–0.057 1.5E-08 0.020 0.013–0.028 8.3E-07
cg16976547 0.001 −0.003–0.005 5.8E-01 0.001 −0.001–0.003 5.4E-01 0.003 −0.006–0.012 4.8E-01 0.001 −0.003–0.005 6.6E-01
Table 3. Difference in methylation in twins discordant according to smoking status in the NTR study for the 
CpG sites associated with lung cancer identified as un-associated with smoking (LC-non-AwS), or associated 
with smoking (LC-AwS) in the NOWAC study. Diff: difference; Bolded numbers for p-values are considered 
significant using a Bonferroni threshold.
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The two LC-non-AwS CpG sites were consistently not associated to smoking exposure in all the analyses per-
formed, which indicates that they are minimally associated with smoking. The association between LC-non-AwS 
CpG sites and risk was stronger in adenocarcinoma cases compared to the other more smoking-induced histolog-
ical subtypes35, which was not the trend observed in LC-AwS markers. Although hampered by statistical power in 
stratified analyses of never smokers, the same two LC-non-AwS markers were found to be statistically significant, 
along with 10 of the LC-AwS CpGs. Comparing pairs of smoking discordant twins revealed no difference in 
methylation levels at LC-non-AwS CpG sites. Finally, the two LC-non-AwS CpGs were not identified in the large 
meta-analyses for epigenetic smoking signatures14 and we did not identify any single-nucleotide polymorphisms 
reported in the vicinity of these two sites36, hence arguing against possible genetic confounding. Taken together, 
this supports that the two LC-non-AwS CpG sites, and in particular cg10151248-PC, are not associated with 
smoking and are distinct from the LC-AwS markers.
To enable deeper investigation of the functional role of the methylation changes at the LC-non-AwS CpG 
sites, we defined ‘second order’ CpG sites as being associated with the methylation levels at any of these two 
LC-non-AwS CpG sites but not directly with lung cancer risk. None of the 160 CpG sites associated with 
cg10151248-PC were associated with smoking status in a recent large meta-analysis of DNA methylation and 
smoking status14, and 22 of the 1,876 for cg13482620-B3GNTL1 (1.2%) were reported as LC-AwS markers. On 
this basis, we explored whether the two non-LC-AwS markers and complemented list of markers less associated 
with smoking could provide novel pathway information relevant for lung cancer development.
The candidate methylation markers were further investigated by exploring the association between methyl-
ation levels at lung cancer related markers and gene expression data available in the same individuals. In order 
to ensure a comprehensive search for distinguishable pathways the full sets of markers were explored separately 
for the LC-AwS and LC-non-AwS CpG sites. Because regulation of gene expression through differential methyl-
ation obeys complex and multivariate mechanisms and can operate remotely (‘trans’ effects)37, all assayed tran-
scripts were investigated. No transcript was directly associated with methylation levels at cg10151248-PC and 
cg13482620-B3GNTL1 (neither PC or B3GNTL1 transcripts) which may not be surprising as both are highly 
methylated and show small, although significant, differences between cases and controls. However, we iden-
tified associations between methylation levels at the ‘second order’ CpG sites, and transcripts. The significant 
CpG-transcript pairs for the 160 cg10151248-PC-related CpG sites involved 19 transcripts, none of which were 
AwS markers either in our data or in the large meta-analysis of gene expression data38, while 33 of 127 transcripts 
involved in cg13482620-B3GNTL1-related CpG-transcript pairs were identified in the large meta-analysis38.
In the exploration of LC-non-AwS markers of lung cancer, which are likely to be more subtle signals than 
LC-AwS markers, an enriched CpG list was assessed when comparing potential functional roles of the differ-
ent sets of markers identified. The gene ontology categories identified for the transcripts of the ‘second order’ 
CpG sites of cg10151248-PC and cg13482620-B3GNTL1, showed a large degree of overlap for categories linked 
to immune responses. The genes and consequently the categories indicated for cg10151248-PC clearly differed 
from those derived from LC-AwS CpG sites (categories linked to response to external stressors). Results from 
cg13482620-B3GNTL1 showed similarity with those from cg10151248-PC but also exhibited some common 
CpG Name Gene Chromosome
No. of significant 
transcripts
cg10151248- PC associated
cg21570493 NA 1 19
cg13482620- B3GNTL1 associated
cg03160057 WDR66 12 104
cg10115918 B3GNTL1 17 11
cg05664421 ZFYVE28 4 10
cg13752749 CRB2 9 1
cg01676996 C6orf136 6 2
cg11654904 ZNF642 1 6
cg04909834 ARHGEF10 8 1
cg06836020 LOC440354 16 1
cg27665823 DECR2 16 1
LC-AwS CpG sites
cg06126421 NA 6 75
cg05575921 AHRR 5 43
cg01940273 NA 2 19
cg21566642 NA 2 10
cg03636183 F2RL3 19 7
cg21161138 AHRR 5 7
cg02451831 KIAA0087 7 4
cg25305703 NA 8 3
Table 4. The number of transcripts associated to the ‘second-order’ CpGs un-associated with smoking (LC-
non-AwS) and the CpGs associated with smoking (LC-AwS).
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categories with LC-AwS sites. Thus indicating that a wide search provided novel information on potential path-
ways of relevance for lung cancer.
There is very limited evidence in the literature linking the methylation or expression levels at the two 
LC-non-AwS CpG sites and health outcomes. Notably, the CpG methylations of PC and B3GNTL1 (located in 
unknown gene region and shelf region, respectively) were not associated with transcript expression for same 
genes. Nevertheless, hypermethylation at another CpG site in the gene B3GNTL1 has been observed in colorectal 
tumors compared to adjacent tissue39 and the upregulated expression of this gene has been indicated as a poten-
tial marker for colorectal cancer40. Conversely, to the best of our knowledge there are no reported characterized 
description of the downstream consequences of altered methylation levels at cg10151248-PC.
Residual confounding by smoking in our adjusted analyses cannot be disregarded. However, CSI appeared 
to be a stringent adjustment for exposure to smoking and the argumentation above supports the manner in 
which we classified markers as being LC-AwS or LC-non-AwS (or not directly for cg13482620-B3GNTL1). 
Further, adjustment for estimates of white blood cell composition were not emphasized here due to the potential 
over-adjustment by smoking.
In conclusion, using blood-derived DNA methylation and gene expression profile from a prospective lung 
cancer study in Norwegian women, our study identified 25 differentially methylated CpG sites prior to lung can-
cer diagnosis, of which two appeared to be LC-non-AwS, in particular cg10151248-PC. These LC-non-AwS CpG 
sites seemed to be involved in biological pathways distinct from those related to LC-AwS CpG sites, and linked 
to immunological changes in blood prior to cancer diagnosis. Although the study size is limited, the use of a 
stringent significance level when assessing DNA methylation and gene expression data has revealed markers that 
represent prospective population-specific markers of smoking exposure as well as markers potentially relevant to 
lung cancer development and warrant further study.
Availability of Data and Material
The microarray data generated and/or analysed in the current study could be accessed upon reasonable request to 
the originating cohort. Access will be conditional to adherence to local ethical and security policy. R codes used 
for the analyses presented in the paper are available upon request.
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